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Background: Hepatocyte carcinoma (HCC) is one of the most common malignancies worldwide. Despite many
achievements in diagnosis and treatment, HCC mortality remains high due to the malignant nature of the disease.
Novel approaches, especially for targeted therapy, are being extensively explored. Gene therapy is ideal for such purpose
for its specific expression of exogenous genes in HCC cells driven by tissue-specific promoter. However strategies based
on correction of mutations or altered expressions of genes responsible for the development/progression of HCC have
limitations because these aberrant molecules are not presented in all cancerous cells. In the current work, we adopted
a novel strategy by targeting the DNA replication step which is essential for proliferation of every cancer cell.
Methods: A recombinant adenovirus with alpha fetoprotein (AFP) promoter-controlled expressions of artificial microRNAs
targeting DNA polymerases α, δ, ε and recombinant active Caspase 3, namely Ad/AFP-Casp-AFP-amiR, was constructed.
Results: The artificial microRNAs could efficiently inhibit the expression of the target polymerases in AFP-positive HCC
cells at both RNA and protein levels, and HCC cells treated with the recombinant virus Ad/AFP-Casp-AFP-amiR exhibited
significant G0/1 phase arrest. The proliferation of HCC cells were significantly inhibited by Ad/AFP-Casp-AFP-amiR with
increased apoptosis. On the contrary, the recombinant adenovirus Ad/AFP-Casp-AFP-amiR did not inhibit the expression
of DNA polymerases α, δ or ε in AFP-negative human normal liver cell HL7702, and showed no effect on the cell cycle
progression, proliferation or apoptosis.
Conclusions: Inhibition of DNA polymerases α, δ and ε by AFP promoter-driven artificial microRNAs may lead to effective
growth arrest of AFP-positive HCC cells, which may represent a novel strategy for gene therapy by targeting the genes
that are essential for the growth/proliferation of cancer cells, avoiding the limitations set by any of the individually
altered gene.
Keywords: Hepatocellular carcinoma, Gene therapy, Artificial microRNA, DNA polymerase, Caspase 3Background
Hepatocellular carcinoma (HCC) is one of the most
frequently diagnosed cancers and one of the leading
causes of cancer death in both men and women world-
wide, and HCC incidence rates are increasing in many
parts of the world [1-4]. Despite of the achievements in
early diagnosis and treatment, HCC mortality remains
high due to its malignant nature. At present, surgical
resection and liver transplantation remain to be the
most curative treatment for early stage HCC. Nevertheless,* Correspondence: caoj@zju.edu.cn; zhenyujia@yahoo.com
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unless otherwise stated.patients recurrence is up to 70% within five years after
surgical section; the strict surgical indications, limited
liver donors and high costs restrict liver transplantation
to only a minority of patients. Nonsurgical treatments
include percutaneous ablation, transarterial chemo-
embolization, radioembolization and systemic chemo-
therapy [1,3-5].
As a new form for cancer treatment, gene therapy
has been used for certain cancers, and a number of
clinical trials including phase I, II and III trials for
various cancers are underway [6,7]. Recent gene ther-
apy for HCC is still confined to pre-clinical laboratory
investigations, focusing on single or multiple genes
dysregulated/mutated in HCC cells [8-12]. Gene therapy
exhibits synergistic antitumor ability when combined withs is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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tions or aberrant expressions of those target genes are
highly variable in HCC, the strategy targeting one or a few
of alterations may only be effective for a small group of
patients. It is highly desirable to develop a novel strategy
that will be effective for more, if not all, HCC.
DNA replication is one of the key steps for cell prolifera-
tion, and DNA polymerase is essential for DNA replica-
tion [17]. Inhibition of DNA polymerase expression by
gene-silencing should therefore be sufficient to block the
proliferation of cancer cells. Apoptosis, a natural biological
progress which can be triggered by intrinsic mitochondrial
pathway and extrinsic death receptor pathway [18,19],
plays a crucial role in eliminating excess or abnormal cells
and which is often impaired in cancer. Endogenous
pro-Caspase 3 is unable to induce apoptosis, and Caspase
3 activity also determines the chemosensitivity of cancer
cells [20]. Therefore we hypothesized that the combin-
ation of silencing DNA polymerases and enforcing expres-
sion of recombinant active Caspase 3 should have potent
antitumor effect which may inhibit cell proliferation while
trigger apoptosis.
In the current study, a combination of AFP enhancer
and AFP basal promoter was adopted to modulate the
HCC specific expression of artificial microRNAs targeting
DNA polymerases α, δ and ε simultaneously with consti-
tutively active recombinant Caspase 3 in an adenoviral
vector. Serum alpha-fetoprotein (AFP) is extensively used
as a tumor biomarker [21], and its promoter is therefore
widely used to achieve HCC-specific gene expression with
different enhancer/promoter combinations to confer high
level while tight control of downstream gene expression in
AFP-positive hepatoma cells [22-25]. The recombinant
adenovirus presented in this work showed potent anti-
tumor efficacy targeting AFP-positive HCC.
Methods
Cell culture
Human hepatocellular carcinoma cell lines HepG2
(ATCC, Manassas, VA, USA; B-8065) and Hep3B (ATCC,
HB-8064) purchased from American Type Culture Collec-
tion (ATCC) were maintained in RPMI 1640 medium
(Life Technologies, Carlsbad, CA, USA; 22400–105)
supplemented with 10% heat-inactivated bovine growth
serum (BGS) (Thermo Scientific, Waltham, MA, USA;
SH30541.03). Human normal liver cell line HL-7702
(Shanghai Institute of Cellular Biology of Chinese
Academy of Sciences, Shanghai, China; GNHu6) was
maintained in RPMI 1640 medium with 10% heat-
inactivated fetal bovine serum (FBS) (Life Technolo-
gies,10099-141). Human embryonic kidney cell line
Adeno-X-293 (Clontech Laboratories, Mountain View,
CA, USA; 632271) was maintained in low glucose
Dulbecco’s Minimum Essential Medium (DMEM) (LifeTechnologies,12320-032) supplemented with 10% BGS.
All cells were cultured at 37°C and 5% CO2 with saturated
humidity and splitted when reach confluency.Generation of recombinant adenovirus
Construction of pDC312/AFP-Casp-AFP-amiR
A 1018 bp hepatocyte-specific recombinant AFP enhancer/
promoter composed of the enhancer region from −4120
to −3300 and the basal promoter from −180 to +1 of hu-
man AFP gene was cloned as previously reported [26].
Constitutively active recombinant caspase 3 gene was
cloned as previously described [27], and subcloned
into adenoviral shuttle plasmid pDC312 (Microbix
Biosystems, Toronto, ON, Canada) under recombinant
AFP enhancer/promoter to form a Caspase 3 expres-
sion cassette as shown in Figure 1A. DNA sequences
of artificial miRNAs targeting DNA polymerases α, δ
and ε were based on natural structure of human miR-
30 (miRBase accession number : MI0000088) and core
sequences were acquired from RNAi Codex (http://
cancan.cshl.edu/cgi-bin/Codex/Codex.cgi) (Figure 1A).
These DNA fragments were cloned by two rounds of
overhang extension PCR with cycling condition: 95°C,
2 min; 95°C, 30s, 58°C, 30s, 72°C, 30s, 30 cycles; 72°C,
5 min [28].Primers are listed in Table 1. Briefly, the
97 bp products of the first round PCR amplification
were used as templates for the second round amplification,
and the 142 bp final PCR products were cloned into
pMD19-T (TaKaRa Bio, Otsu, Shiga, Japan; D102A) and
sequenced by Invitrogen (Shanghai, China). Correct se-
quences were cloned into expression vector pIRES2-EGFP
(Clontech Laboratories, 6029–1). The tandem repeats of
artificial miRNAs were ligated into adenoviral shuttle vec-
tor pDC312 under recombinant AFP enhancer/promoter
to form the artificial miRNAs expression cassette AFP-
amiR, followed by the AFP-Casp expression cassette in the
same orientation, as schematically depicted in Figure 1B.
Transcription terminal signal was cloned from the BGH
polyA of pcDNA3.1 (+) (Life Technologies, V790-20). The
resulting shuttle vector was designated as pDC312/AFP-
Casp-AFP-amiR. Another plasmid, pDC312/AFP, an empty
vector without exogenous genes was constructed as
control as schematically described in Figure 1B. Every two
neighbouring fragments were ligated by BamHI/BglII
(New England Biolabs, Ipswich, MA, USA; R0136/R0144)
cohesive ends [29].
Packaging, characterization, propagation, purification and
titration of recombinant adenovirus
The adenoviral shuttle plasmids pDC312/AFP-Casp-
AFP-amiR and pDC312/AFP were cotransfected with
adenoviral backbone plasmid pBGHlox(delta)E1,3Cre
vector (Microbix Biosystems) by Lipofectamine LTX
Figure 1 Illustration of hairpin structure of artificial microRNAs and recombinant adenoviruses. A: DNA sequences of artificial miRNAs targeting
DNA polymerases α, δ and ε were based on natural structure of human miR-30. The bolds were core sequences acquired from RNAi Codex.
B: a) Recombinant adenovirus Ad/AFP-Casp-AFP-amiR containing two expression cassettes to express artificial microRNAs targeting DNA polymerase
α, δ, ε and active recombinant Caspase3. b) Recombinant adenovirus Ad/AFP only containing AFP promoter used as control.
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293 cells respectively. Supernatant were analyzed to
characterize the generation of recombinant adenoviruses
performed by PCR amplification of inserted exogenous
gene sequences. Primers and reaction conditions are listed
in Table 2. The recombinant adenoviruses were propa-
gated by infecting Adeno-X™ 293 cells with 5% serum
DMEM in large scale and infected cells shown cytopathic
effect (CPE) in 48 h were harvested. Virus particles werereleased by three rounds of freeze-thaw cycle at −80°C
and 37°C and purified by Adeno-X Maxi Purification Kit
(Clontech Laboratories, 631533) for in vitro assay. Purified
viruses were dialyzed using by sterile Slide-A-Lyzer Dialy-
sis (Thermo-Pierce, Rockford, IL, USA; 66453) with viral
storage buffer (20 mM Tris.Cl pH8.0, 25 mM NaCl, 2.5%
glycerol(w/v)). Infectious units (ifu) of dialyzed viruses
were titrated by Adeno-X Rapid Titer Kit (Clontech
Laboratories, 632250) following the manufacturer’s
Table 1 PCR primers for amplification of artificial microRNAs
artificial microRNA primer sequence product size(bp)
miR-polα 1st round F: 5-TGCTGTTGACAGTGAGCGCGCAGATCATGTGTGAGCTAAATAGTGAAGCCACAGATGTA-3 97
R: 5-TCCGAGGCAGTAGGCATGCAGATCATGTGTGAGCTAAATACATCTGTGGCTTCACTATT-3
2nd round F: 5-AGATCTGATCCAAGAAGGTATATTGCTGTTGACAGTGAGCG-3 142
R: 5-GGATCCATCGTAGCCCTTGAAGTCCGAGGCAGTAGGCA-3
miR-polδ 1st round F: 5-TGCTGTTGACAGTGAGCGACGGGACCAGGGAGAATTAATATAGTGAAGCCACAGATGTA-3 97
R: 5-TCCGAGGCAGTAGGCAGCGGGACCAGGGAGAATTAATATACATCTGTGGCTTCACTATA-3
2nd round F: 5-AGATCTGATCCAAGAAGGTATATTGCTGTTGACAGTGAGCG-3 142
R: 5-GGATCCATCGTAGCCCTTGAAGTCCGAGGCAGTAGGCA-3
miR-polε 1st round F: 5-TGCTGTTGACAGTGAGCGAGGTTCCCACTTGCTGCTCAATTAGTGAAGCCACAGATGTA-3 97
R: 5-TCCGAGGCAGTAGGCACGGTTCCCACTTGCTGCTCAATTACATCTGTGGCTTCACTAAT-3
2nd round F: 5-AGATCTGATCCAAGAAGGTATATTGCTGTTGACAGTGAGCG-3 142
R: 5-GGATCCATCGTAGCCCTTGAAGTCCGAGGCAGTAGGCA-3
The bold italics indicate restriction endonuclease sites for cloning.
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Cell viability assay by MTT
HepG2, Hep3B and HL7702 cells were seeded in 24-well
cell culture plates with 1 × 104 in 0.5 ml complete
medium per well, and infected with multiplicity of infec-
tion (MOI) 50 by Ad/AFP-Casp-AFP-amiR and Ad/AFP
respectively in triplicates. Cell viability was determined
by MTT assay using thiazolyl blue tetrazolium bromide
(Sigma, St. Louis, MO, USA; M2128). At designated
time point post infection, the infected cells were incu-
bated with MTT solution with a final concentration of
0.5 mg/ml for 4 h at 37°C, 5% CO2 and saturated
humidity. Medium was aspirated, 250 μl isoproponal
was added per well to dissolve purple crystals and 100 μl
of the dissolved solution was transferred into a 96-well
plate for measurement of absorbance at 570 nm with a
690 nm reference by Molecular Device Spectra Max M4
Microplate Reader. Relative cell viability was calculated
with the non-infected cells as controls. Experiment was
repeated at least twice.Table 2 PCR primers and reaction conditions for identification





AFP promoter F: 5-AGATCTCAGATTGAATTATTTGC-3
R: 5-GGATCCAAATCATGCTGAAATT-3
recombinant caspase3 F: 5-AGATCTGGCTAACTAGAGAACCCA-3
R: 5-GGATCCCCCATCAACTTCATCGTGATAAAAATAG
The bold italics indicate restriction endonuclease sites for cloning.Flow cytometry analysis of cell apoptosis by Annexin V-PI
staining
HepG2, Hep3B and HL7702 cells were seeded in 6-well
cell culture plate with total number 6 × 105, 8 × 105 and
5 × 105 respectively, and infected with recombinant
adenoviruses at MOI 50 for 72 h. Infected cells were
collected by centrifugation and washed with phosphate-
buffered saline (PBS). Early apoptosis was detected by
flow cytometry with FITC-Annexin V Apoptosis Detec-
tion Kit (BD Biosciences Pharmingen, San Diego,
California, USA; 556547) following the manufacturer’s
instruction. Experiment was repeated at least 3 times.
Cell cycle examined by PI staining coupled with flow
cytometry
HepG2, Hep3B and HL7702 cells were seeded in 6-well
cell culture plate with total number 2 × 106, 4 × 106 and
1 × 106 respectively, and infected with recombinant
adenoviruses at MOI 50 for 48 h. Infected cells were col-
lected by centrifugation, fixed in 75% pre-chilled ethanol
at 4°C overnight and washed with PBS and stained by
staining solution containing 50 μg/ml Propidium Iodideof recombinant adenoviruses
PCR reaction condition product size(bp)
GTGAGCG-3 95°C , 5 min; 94°C , 30s, 50°C , 30s,
72°C , 45 s, 35 cycles; 72°C , 5 min
142, 284, 426
AGGCA-3
95°C , 5 min; 94°C , 30s, 53°C , 30s,
72°C , 30s, 35 cycles; 72°C , 5 min
237
95°C , 5 min; 94°C , 30s, 55°C , 30s,
72°C , 90s, 35 cycles; 72°C , 5 min
1018
95°C , 5 min; 94°C , 30s, 58°C , 30s,
72°C , 60s, 35 cycles; 72°C , 5 min
610
AGTTC-3
Table 3 Quantitative PCR primers for determination of mRNA expression levels of polymerase α, δ, ε, AFP and β-actin
gene detected gene code primer sequence product size(bp)
polymerase α NM_016937.3 F: 5- TTCTGACAAGTCCCTGTACACC −3 240
R: 5- TAGGATTTCACGGCACAACCA −3
polymerase δ NM_002691.3 F: 5- CCCTACGTGATCATCAGTGC −3 107
R: 5- AGGTAGTACTGCGTGTCAATGG −3
polymerase ε NM_006231.2 F: 5- CCTACGACTCCTCTGCCATC −3 219
R: 5- CGTAGTGCTGGGCAATGTTC −3
AFP NM_001134.1 F: 5- ACCTCGTCGGAGCTGATGG −3 204
R: 5- TGGCCTCCTGTTGGCATATG −3
β-actin NM_001101.3 R: 5- CCGATCCACACGGAGTACTT −3 406
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Itasca, IL, USA; A0051), 0.1% Triton X-100 (Amresco,
Solon, OH, USA; 0694) at 37°C for 30 min in dark. Cell
cycle profiles were analyzed by flow cytometry. Experi-
ment was repeated at least three times.
Real time quantitative PCR
HepG2, Hep3B and HL7702 cells were seeded in 6-well
cell culture plate with total number 1.2 × 106, 1.6 × 106
and 5 × 105 respectively, and infected with recombinant
adenoviruses at MOI 50 for 48 h. Total RNA was
extracted by RNeasy Plus Mini Kit (Qiagen, Hilden,
Germany; 74134), and reverse transcribed to cDNA byFigure 2 Relative expression level of AFP in three cell lines. AFP and
β - actin mRNA levels of HCC cells HepG2, Hep3B and normal liver
cell HL7702 were quantified by fluorescent real time quantitative
PCR. β-Actin was used as the internal control to calculate the relative
mRNA level of AFP.M-MLV Reverse Transcriptase (Promega, Madison, WI,
USA; M1701). Fluorescent real time PCR with Quanti-
Fast SYBR Green PCR (Qiagen, 204054) was performed
to examine the mRNA levels of AFP, DNA polymerase
α, δ and ε, with β-Actin as a normalization control ac-
cording to the manufacturer’s instruction. Triplicates
were set up for each sample and experiment was
repeated at least twice. Primers were listed in Table 3.Western blotting
Cells were plated and infected with recombinant adenovi-
ruses in the same manner as that for qPCR. Cells were har-
vested 48 h after infection and lysed. Protein concentration
was determined by BCA protein assay kit (Thermo-Pierce,
23227) and samples were subject to SDS-PAGE followed
by electrotransfer onto PVDF immobilon-P membrane
(Merck Millipore, Billerica, MA,USA; IPVH00010). Anti-
bodies against DNA polymerase α (SANTA CRUZ, Dallas,
Texas, USA; sc-5921), DNA polylmerase δ (SANTA
CRUZ, sc-8800), DNA polymerase ε (SANTA CRUZ,
sc-56655), Caspase 3 (Cell Signaling Technology, Danvers,
MA, USA; 9662S) and β-Actin (SANTA CRUZ; sc-47778)
were used as primary antibodies. Specific bands were visu-
alized by Clarify Western ECL Substrate (Bio-Rad Labora-
tories, Hercules, CA, USA; 170–5061) with Gel Imaging
and System (Alpha Innotech Corporation, Randburg,
South Africa; FC2) and relative protein expression level
was calculated by AlphaVIEW SA software. β-Actin
was probed on the same PVDF membrane as an internal
control for protein equal loading. Experiment was re-
peated at least twice.Statistics
All data were presented as mean value ± standard deviation
(SD). P-values between treatment and control groups were
analyzed by unpaired Student’s t-test. P < 0.05 was consid-
ered statistically significant.
Figure 3 (See legend on next page.)
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Figure 3 Ad/AFP-Casp-AFP-amiR inhibited expression of DNA polymerases in HCC cell lines. A: Ad/AFP-Casp-AFP-amiR inhibited mRNA
expression of DNA polymerases in HCC cell lines. DNA polymerase α, δ, ε and β-actin mRNA levels of HCC cells HepG2, Hep3B and normal liver
cell HL7702 were quantified by fluorescent real time quantitative PCR after infected by two adenoviruses with MOI 50 respectively for 48 h.
β-Actin was used as the internal control to calculate the relative mRNA levels of DNA polymerase α, δ, ε. The relative mRNA level of blank
control was set as 100%. *P < 0.05, **P < 0.01, ***P < 0.001, n = 3. B: Ad/AFP-Casp-AFP-amiR inhibited protein expression of DNA polymerases
in HCC cell lines. DNA polymerase α, δ, ε and β-actin protein levels of HCC cells HepG2, Hep3B and normal liver cell HL7702 were monitored
by Western blot after infected by two adenoviruses with MOI 50 respectively for 48 h. C: The grey values of the DNA polymerase α, δ, ε and β-actin
were calculated by AlphaVIEW SA software. β-Actin was used as the internal control to calculate the relative protein levels of DNA polymerase α, δ, ε.
The relative mRNA level of blank control was set as 100%. *P < 0.05, **P < 0.01, ***P < 0.001, n = 3.
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Recombinant adenovirus inhibits the expression of DNA
polymerases in HCC cells and decreases S-phase fraction
The recombinant adenovirus Ad/AFP-Casp-AFP-amiR
was constructed with two separate expression cassettes
which express active Caspase 3 and tandem artificial
microRNAs targeting DNA polymerases α, δ and ε re-
spectively as illustrated in Figure 1B. Recombinant
adenovirus Ad/AFP was constructed as control. Two
HCC cells HepG2 and Hep3B and one normal hepato-
cyte cell HL7702 with different AFP expression levels
were used to evaluate the targeted expression. As shown
in Figure 2, high level of AFP mRNA could be detected
by reverse transcription quantitative PCR (RT-qPCR) in
HepG2 cells and low level of AFP mRNA could be de-
tected in Hep3B cells. Relatively low level of AFP mRNA
compared to those in HepG2 and Hep3B cells was
detected in HL7702 cells (considered as AFP-negative).
AFP level in HepG2 was ~ 26 folds higher than that in
Hep3B, ~ 5 × 105 folds higher than that in HL7702. We
first examined the inhibition efficiency of artificial
microRNAs on target mRNAs in these cells 48 h after
infection by the recombinant adenovirus Ad/AFP-Casp-
AFP-amiR. The results showed that only very weak
inhibition in AFP-negative HL7702 cells could be ob-
served, with inhibition rates 12.71% (p < 0.05, n = 3),
14.87% (p < 0.01, n = 3) and 12.06% (p > 0.05, n = 3) for
DNA polymerases α, δ and ε respectively. Higher inhib-
ition could be observed in Hep3B cells which have low
AFP expression, with inhibition rates 25.51% (p < 0.05,
n = 3), 34.33% (p < 0.01, n = 3) and 26.28% (p < 0.01, n = 3)
for DNA polymerases α, δ and ε respectively. StrongFigure 4 Ad/AFP-Casp-AFP-amiR decreased S phase in HepG2. Cell phase
were tested by PI staining with flow cytometry after infected by two adenoinhibition was observed in HepG2 cells which have
high level of AFP expression, with inhibition rates
51.19% (p < 0.001, n = 3), 58.27% (p < 0.001, n = 3) and
51.50% (p < 0.001, n = 3) for DNA polymerases α, δ and ε
respectively (Figure 3A). Western blot results (Figure 3B,
C) also showed that significant decrease of DNA polymer-
ases α, δ and ε at protein level in AFP-expressing HCC
cells, with decrease rates 42.91% (p < 0.05, n = 3), 75.91%
(p < 0.05, n = 3) and 61.03% (p < 0.05, n = 3) respectively in
HepG2, 54.32% (p < 0.05, n = 3), 20.58% (p < 0.05, n = 3)
and 53.96% (p > 0.05, n = 2) respectively in Hep3B, but the
rates were only 22.88% (p > 0.05, n = 3), 14.53% (p > 0.05,
n = 3) and 6.68% (p > 0.05, n = 3) respectively in HL7702,
which were consistent with the inhibitions at mRNA level.
As a consequence of the expression inhibition of DNA
polymerases by specific artificial microRNAs in HCC
cells, the progression of cell cycle were significantly
blocked. Flow cytometric cell cycle analyses showed
retardant cell cycle. After infecting for 48 h, G1 phase
increased significantly by 61.14% (p < 0.01, n = 6) and S
phase decreased significantly by 44.91% (p < 0.05, n = 6)
in high AFP-expressing HepG2 cells, while no statisti-
cally significant alterations were observed for low AFP-
expressing Hep3B cells and AFP-negative HL7702 cells
(Figure 4 and Table 4).
Recombinant adenovirus increases active Caspase 3 in
HCC cells and promotes early apoptosis
The HepG2, Hep3B and HL7702 cells were treated with
the recombinant adenovirus Ad/AFP-Casp-AFP-amiR
for 48 h and analyzed for caspase activation by Western
blot. As shown in Figure 5A, Ad/AFP-Casp-AFP-amiRproportions of HCC cells HepG2, Hep3B and normal liver cell HL7702
viruses with MOI 50 respectively for 48 h. *P < 0.05, **P < 0.01, n ≥ 3.
Table 4 Influence of recombinant adenoviruses on S-phase
Fraction (SPF) of HCC cells
S-Phase fraction P-value
Blank control Ad/AFP Ad/AFP-amiR-AFP-Casp
HepG2 37.25% 42.00% 23.14% <0.01
Hep3B 38.51% 36.55% 45.19% >0.05
HL7702 23.40% 27.21% 25.69% >0.05
P-values between Ad/AFP-Casp-AFP-amiR group and Ad/AFP group were
analyzed by unpaired Student’s t-test.
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Caspase 3 in HepG2 and Hep3B cells, suggesting effective
activation of endogenous caspase cascade by the expres-
sion of recombinant active Caspase 3.
The specific activation of endogenous Caspase 3 in
AFP-positive HCC cells by the recombinant adenovirus
Ad/AFP-Casp-AFP-amiR led to the apoptosis of HCC
cells. After infecting HCC cells for 72 h, Ad/AFP-Casp-
AFP-amiR promoted early apoptosis by 35.97% (p < 0.05,
n = 4) in HepG2, 41.15% (p < 0.05, n = 4) in Hep3B
and 4.66% (p > 0.05, n = 4) in HL7702 respectively by
Annexin V staining followed by flow cytometric examin-
ation, as shown in Figure 5B.
Cell viability assay by MTT also showed significant spe-
cific antitumor potential of Ad/AFP-Casp-AFP-amiR
adenovirus in vitro. After infection for 72 h with MOI 50,Figure 5 Ad/AFP-Casp-AFP-amiR induced cell apoptosis in HCC cell lines. A
Caspase3 in HCC cell lines. Caspase3 and β-actin protein levels of HCC cells
Western blot after infected by two adenoviruses with MOI 50 respectively f
lines. Relative apoptotic cells of HCC cells HepG2, Hep3B and normal liver c
cytometry after infected by two adenoviruses with MOI 50 respectively forcompared to control virus Ad/AFP, Ad/AFP-Casp-AFP-
amiR inhibited HepG2 cell survival by 56.40% (p < 0.001,
n = 5), Hep3B by 5.90% with no significant difference and
HL7702 by 8.72% (p < 0.01,n = 5) respectively (Figure 6).
Discussion
One of the major problems in current cancer gene ther-
apy is the side-effect caused by non-specific expression
of exogenous genes in other cells than cancer cells.
Tumor-specific promoter is a strategy commonly
adopted in many studies nowadays. Since AFP gene is
re-expressed in most HCC cells, its promoter is used as
a regulatory element for HCC-specific expression.
Though highly specific, the basal AFP promoter is weak
in transcription initiation to achieve satisfactory thera-
peutic result. Therefore, an enhancer is often used in
combination with AFP basal promoter for higher
transcription initiation. Up to now, several enhancer-
promoter combinations have been documented to attain
potent and specific transcription in HCC gene therapy
studies, such as the hypoxia-specific enhancer in
combination with the AFP basal promoter [22], the AFP
enhancer in combination with other promoter such as
the housekeeping gene phosphoglycerate kinase (pgk)
[23], and the AFP enhancer in combination with AFP
basal promoter [24,25]. All these combinations exhibited: Ad/AFP-Casp-AFP-amiR increased protein expression of cleaved
HepG2, Hep3B and normal liver cell HL7702 were monitored by
or 48 h. B: Ad/AFP-Casp-AFP-amiR induced cell apoptosis in HCC cell
ell HL7702 were determined by Annexin V staining coupled with flow
72 h. *P < 0.05, n = 4.
Figure 6 Ad/AFP-Casp-AFP-amiR inhibited proliferation of HepG2.
Relative cell viabilities of HCC cells HepG2, Hep3B and normal liver cell
HL7702 were detected by MTT assay after infected by two adenoviruses
with MOI 50 respectively for 72 h. The relative cell viability was the ratio
of treatment to control. **P< 0.01, ***P< 0.001, n = 5.
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achieved by the combination of AFP enhancer with its
basal promoter which has shown high efficiency compar-
able to that of the most widely used non-specific
cytomegalovirus (CMV) promoter [30]. Its high HCC-
specific transcriptional activity is ensured by hepatocyte
nuclear factors 1(HNF1), C/EBP, HNF3 and HNF4
binding to several cis-acting liver-enriched transcription
factors (LETFs) binding sites in AFP enhancer [21,30].
In our study, a recombinant 1018 bp AFP promoter
comprised of the enhancer region from −4120 to −3300
and the basal promoter from −180 to +1 of human AFP
gene showed high HCC-specific activity [26], that the
specific transcriptional factors/activators could bind to
those specific binding sites in AFP enhancer and basal pro-
moter to activate transcription of the downstream genes.
Effective therapeutic gene selection is another import-
ant issue needs to be considered in cancer gene therapy.
Various aberrant genes in malignant cells have been
targeted by different strategies to suppress the over-
expressed genes or to compensate/enforce the expres-
sion of deleted/down-regulated genes. However, one
gene may not work alone, it may be involved in more
than one signaling pathways with interactions. One
phenotype of a cell may be regulated by many genes,
and the expression of one gene may determine many
different aspects of a cell. When one gene is targeted,
several interacting signal pathways may respond with
feedback modulations. Therefore, targeting one to two
individual aberrant genes in cancer cells may not lead
to the expected results. As cells proliferate through
cellular duplication including DNA replication [31], the
indispensable DNA polymerases for DNA replicationare ideal targets for gene therapy. DNA polymerases α,
δ and ε that are responsible for DNA replication were
chosen as our targets, which belong to polymerase family
B and that Pol α initiates onset of DNA replication,
followed by Pol ε and Pol δ which catalyzes leading and
lagging strand synthesis respectively [32]. Artificial micro-
RNA strategy was adopted in the study to mimic the
knockdown of target gene as natural miRNAs do [33,34].
Previous reports showed that the processing of artificial
pre-miRNAs to artificial mature miRNAs was more
efficient when artificial pre-miRNAs were in tandem re-
peats than individual pre-miRNA, and the processed artifi-
cial mature miRNAs further led to more efficient
inhibition on genes expression [29,35]. Therefore, to
achieve better gene silencing, DNA sequences coding for
artificial pre-miRNAs specifically targeting DNA Pol α, δ
and ε were cloned in the same expression cassette (the
artificial pre-miRNAs were simplified as artificial miRNAs
in this paper). Transient transfection assay in Hep3B cells
confirmed that the linearly-arrayed artificial miRNAs miR-
polα-δ-ε expression vector was more potent in inhibiting
Pol α, δ and ε at both mRNA and protein levels than each
of the individual artificial miRNA expression vector (data
not shown). Cancer cells may remain at quiescent state
but not go apoptosis if only DNA replication is blocked by
silencing of DNA polymerases. Caspase 3 is the key apop-
tosis executor responsible for a serial of substrates proteo-
lytic degradation for mitochondrial apoptosis [27]. The
strategy that expressing recombinant active Caspase 3 in
combination with silencing DNA pol α, δ and ε can elicit
significant therapeutic effect. In this work, the recombin-
ant active Caspase 3 and artificial miRNAs were put in
two expression cassettes separately with recombinant AFP
enhancer/promoter and transcription termination signal
bovine growth hormone polyadenylation (BGH poly A).
An extra BGH poly A signal was placed between the two
expressing cassettes to warrant the complete termination
of AFP-Caspase 3.
Our current study showed the expected AFP-dependent
inhibition of the recombinant adenovirus Ad/AFP-Casp-
AFP-amiR on HCC cells. As the expression level of AFP is
not constant in different HCC cells depending on the
transcription efficiency of AFP promoter in a cell-specific
manner, the proliferation-inhibition and apoptosis-
inducing effects of the recombinant virus Ad/AFP-Casp-
AFP-amiR differed in HepG2 and Hep3B cells due to dif-
ferent transcription efficiency of the recombinant Caspase
3 and artificial microRNAs controlled by AFP promoter in
these two cells. For the minor inhibition observed for the
control group, it might be an addition effect of viral
toxicity and leakage expression of exogenous genes. Fur-
ther assessments on the therapeutic value of our current
strategy by in vivo experiments with HCC xenograph
mouse models are needed in future work.
Liu et al. BMC Cancer  (2015) 15:325 Page 10 of 11Conclusions
In summary, the results from current work exhibited
the highly efficient HCC-specific killing potential of the
recombinant adenovirus Ad/AFP-Casp-AFP-amiR by the
combination of HCC-specific AFP enhancer/promoter,
blocking of DNA replication and triggering apoptosis.
This may provide a novel strategy to HCC gene therapy.
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